CoChat
Sign Up
Cited by 32

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Progress in the development of new drugs in Alzheimer's disease

Piau, Antoine, Nourhashémi, F., Hein, C., Caillaud, C., Vellas, B.·2011·The Journal of nutrition, health and aging
DOI 10.1007/s12603-011-0012-xPMC PMC12879621
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12603-011-0012-x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 222

  1. Brookmeyer, 2007, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement, 3, 186, 10.1016/j.jalz.2007.04.381 · DOI · Paper page
  2. Birks, 2006, Cholinesterase inhibitors for Alzheimer's disease, Cochrane Database of Systematic Reviews, 1, CD005593
  3. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006;2: CD003154. · DOI · Paper page
  4. Raina, 2008, Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline, Ann Intern Med, 148, 379, 10.7326/0003-4819-148-5-200803040-00009 · DOI · Paper page
  5. Hardy, 2006, Has the amyloid cascade hypothesis for Alzheimer's disease been proved?, Curr Alzheimer Res, 3, 71, 10.2174/156720506775697098 · DOI
  6. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  7. Ghiso, 2001, Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia, J Alzheimers Dis, 3, 65, 10.3233/JAD-2001-3110 · DOI
  8. Iqbal, 2006, Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective, J Alzheimers Dis., 9, 219, 10.3233/JAD-2006-9S325 · DOI
  9. Iqbal, 2008, Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention, J Cell Mol Med, 12, 38, 10.1111/j.1582-4934.2008.00225.x · DOI
  10. Iqbal, 2005, Pharmacological approaches of neurofibrillary degeneration, Curr Alzheimer Res, 2, 335, 10.2174/1567205054367810 · DOI
  11. Zheng, 2002, Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures, Neuroscience, 115, 201, 10.1016/S0306-4522(02)00404-9 · DOI · Paper page
  12. Arriagada, 1992, Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease, Neurology, 42, 631, 10.1212/WNL.42.3.631 · DOI · Paper page
  13. Blennow, 2004, Cerebrospinal fluid protein biomarkers for Alzheimer's disease, NeuroRx, 1, 213, 10.1602/neurorx.1.2.213 · DOI
  14. Selkoe, 2003, Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics, Annu Rev Pharmacol Toxicol, 43, 545, 10.1146/annurev.pharmtox.43.100901.140248 · DOI
  15. Morgan, 2000, A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408, 982, 10.1038/35050116 · DOI
  16. Lavie, 2004, EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials, J Mol Neurosci, 24, 105, 10.1385/JMN:24:1:105 · DOI
  17. Orgogozo, 2003, Subacute meningoencephalitis in a subset of patients with AD after ABeta42 immunization, Neurology, 61, 46, 10.1212/01.WNL.0000073623.84147.A8 · DOI · Paper page
  18. Hock, 2003, Antibodies against Beta-amyloid slow cognitive decline in Alzheimer's disease, Neuron, 38, 547, 10.1016/S0896-6273(03)00294-0 · DOI
  19. Woodhouse, 2007, Vaccination strategies for Alzheimer's disease: A new hope?, Drugs Aging, 24, 107, 10.2165/00002512-200724020-00003 · DOI
  20. Pride, 2008, Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis, Neurodegener Dis, 5, 194, 10.1159/000113700 · DOI
  21. Goni, 2005, New directions towards safer and effective vaccines for Alzheimer's disease, Curr Opin Mol Ther, 7, 17
  22. Rakover, 2007, Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels, Neurodegener Dis, 4, 392, 10.1159/000103250 · DOI
  23. Dodel, 2004, Intravenous immunoglobulins containing antibodies against Beta-amyloid for the treatment of Alzheimer's disease, J Neurol Neurosurg Psychiatry, 75, 1472, 10.1136/jnnp.2003.033399 · DOI
  24. Lichtenthaler, 2004, Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model, J Clin Invest, 113, 1384, 10.1172/JCI21746 · DOI
  25. Luo, 2001, Mice deficient in BACE1, the Alzheimer's Betasecretase, have normal phenotype and abolished Beta-amyloid generation, Nat Neurosci, 4, 231, 10.1038/85059 · DOI · Paper page
  26. Hussain, 2007, Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo, J Neurochem, 100, 802, 10.1111/j.1471-4159.2006.04260.x · DOI
  27. Rajendran, 2008, Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting, Science, 320, 520, 10.1126/science.1156609 · DOI
  28. Comery, 2005, Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease, J Neurosci, 25, 8898, 10.1523/JNEUROSCI.2693-05.2005 · DOI
  29. Dovey, 2001, Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain, J Neurochem, 76, 173, 10.1046/j.1471-4159.2001.00012.x · DOI
  30. Hartmann, 2001, Implication of APP secretases in notch signaling, J Mol Neurosci, 17, 171, 10.1385/JMN:17:2:171 · DOI
  31. Barten, 2006, Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity, Drugs R D, 7, 87, 10.2165/00126839-200607020-00003 · DOI
  32. Wong, 2004, Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation, J Biol Chem, 279, 12876, 10.1074/jbc.M311652200 · DOI
  33. Siemers, 2005, Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers, Clin Neuropharmacol, 28, 126, 10.1097/01.wnf.0000167360.27670.29 · DOI
  34. Siemers, 2007, Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-beta After Inhibition of gamma-Secretase, Clin Neuropharmacol, 30, 317, 10.1097/WNF.0b013e31805b7660 · DOI
  35. Siemers, 2006, Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease, Neurology, 66, 602, 10.1212/01.WNL.0000198762.41312.E1 · DOI
  36. Frick, 2008, P4-366: GSI-953, a potent and selective gammasecretase inhibitor: Modulation of beta-amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans, Alzheimer's and Dementia, 4, T781, 10.1016/j.jalz.2008.05.2437 · DOI
  37. Sun, 2005, Protein kinase C isozymes: memory therapeutic potential, Curr Drug Targets CNS Neurol Disord, 4, 541, 10.2174/156800705774322120 · DOI
  38. Etcheberrigaray, 2004, Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice, Proc Natl Acad Sci U S A, 101, 11141, 10.1073/pnas.0403921101 · DOI
  39. Wilcock, 2008, Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial, Lancet Neurol, 7, 483, 10.1016/S1474-4422(08)70090-5 · DOI
  40. Nalivaeva, 2008, Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease, Curr Alzheimer Res, 5, 212, 10.2174/156720508783954785 · DOI
  41. Leissring, 2003, Enhanced proteolysis of Beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death, Neuron, 40, 1087, 10.1016/S0896-6273(03)00787-6 · DOI
  42. Yasojima, 2001, Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain, Brain Res, 919, 115, 10.1016/S0006-8993(01)03008-6 · DOI
  43. Marr, 2003, Neprilysin gene transfer reduces human amyloid pathology in transgenic mice, J Neurosci, 23, 1992, 10.1523/JNEUROSCI.23-06-01992.2003 · DOI
  44. Saito, 2005, Somatostatin regulates brain amyloid Beta peptide ABeta42 through modulation of proteolytic degradation, Nat Med, 11, 434, 10.1038/nm1206 · DOI
  45. Iwata, 2005, Metabolism of amyloid-beta peptide and Alzheimer's disease, Pharmacol Ther, 108, 129, 10.1016/j.pharmthera.2005.03.010 · DOI
  46. Tokita, 2005, FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats, Eur J Pharmacol, 527, 111, 10.1016/j.ejphar.2005.10.022 · DOI
  47. Jacobsen, 2008, Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade, Proc Natl Acad Sci U S A, 105, 8754, 10.1073/pnas.0710823105 · DOI
  48. Aisen, 2005, The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors, CNS Drugs, 19, 989, 10.2165/00023210-200519120-00002 · DOI
  49. Gervais, 2007, Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis, Neurobiol Aging, 28, 537, 10.1016/j.neurobiolaging.2006.02.015 · DOI
  50. Aisen, 2006, A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease, Neurology, 67, 1757, 10.1212/01.wnl.0000244346.08950.64 · DOI
  51. Wright, 2006, Tramiprosate, Drugs Today (Barc), 42, 291, 10.1358/dot.2006.42.5.973584 · DOI
  52. Finefrock, 2003, Current status of metals as therapeutic targets in Alzheimer's disease, J Am Geriatr Soc, 51, 1143, 10.1046/j.1532-5415.2003.51368.x · DOI
  53. Cuajungco, 2005, Amyloid-beta metal interaction and metal chelation, Subcell Biochem, 38, 235, 10.1007/0-387-23226-5_12 · DOI
  54. Lee, 2004, The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice, Neurobiol Aging, 25, 1315, 10.1016/j.neurobiolaging.2004.01.005 · DOI
  55. Sampson, 2008, Metal protein attenuating compounds for the treatment of Alzheimer's disease, Cochrane Database Syst Rev, 1, CD005380
  56. Liu, 2005, Nanoparticle and other metal chelation therapeutics in Alzheimer disease, Biochim Biophys Acta, 1741, 246, 10.1016/j.bbadis.2005.06.006 · DOI
  57. Lannfelt, 2008, Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial, Lancet Neurol, 7, 779, 10.1016/S1474-4422(08)70167-4 · DOI · Paper page
  58. Jick, 2000, Statins and the risk of dementia, Lancet, 356, 1627, 10.1016/S0140-6736(00)03155-X · DOI
  59. Canevari, 2007, Alzheimer's disease and cholesterol: the fat connection, Neurochem Res, 32, 739, 10.1007/s11064-006-9200-1 · DOI
  60. Cordy, 2006, The involvement of lipid rafts in Alzheimer's disease, Mol Membr Biol, 23, 111, 10.1080/09687860500496417 · DOI · Paper page
  61. Sparks, 2005, Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results, Arch Neurol, 62, 753, 10.1001/archneur.62.5.753 · DOI · Paper page
  62. Simons, 2002, Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial, Ann Neurol, 52, 346, 10.1002/ana.10292 · DOI
  63. Jones, 2008, The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics, Alzheimers Dement, 4, 145, 10.1016/j.jalz.2008.02.001 · DOI
  64. Stuchbury, 2005, Alzheimer's associated inflammation, potential drug targets and future therapies, J Neural Transm, 112, 429, 10.1007/s00702-004-0188-x · DOI
  65. Lue, 2001, Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism, Exp Neurol, 171, 29, 10.1006/exnr.2001.7732 · DOI · Paper page
  66. Onyango, 2005, Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE), Mol Cell Neurosci, 29, 333, 10.1016/j.mcn.2005.02.012 · DOI
  67. Maczurek, 2008, Inflammation and the redox-sensitive AGERAGE pathway as a therapeutic target in Alzheimer's disease, Ann N Y Acad Sci, 1126, 147, 10.1196/annals.1433.026 · DOI
  68. Drewes, 2004, MARKing tau for tangles and toxicity, Trends Biochem Sci, 29, 548, 10.1016/j.tibs.2004.08.001 · DOI
  69. Phiel, 2003, GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides, Nature, 423, 435, 10.1038/nature01640 · DOI
  70. Huang, 2006, Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease, Curr Drug Targets., 7, 1389, 10.2174/1389450110607011389 · DOI
  71. Zhao, 2003, Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts, Neurobiol Dis, 14, 458, 10.1016/S0969-9961(03)00124-4 · DOI
  72. Tanimukai, 2005, Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease, Am J Pathol, 166, 1761, 10.1016/S0002-9440(10)62486-8 · DOI · Paper page
  73. Wang, 2007, Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration, Eur J Neurosci, 25, 59, 10.1111/j.1460-9568.2006.05226.x · DOI
  74. Wei, 2002, Dephosphorylation of tau protein by calcineurin triturated into neural living cells, Cell Mol Neurobiol, 22, 13, 10.1023/A:1015385527187 · DOI
  75. Lian, 2001, Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex, Exp Neurol, 167, 158, 10.1006/exnr.2000.7534 · DOI
  76. Hong, 1997, Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3, J Biol Chem, 272, 25326, 10.1074/jbc.272.40.25326 · DOI
  77. Rametti, 2008, Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection, Neurosci Lett, 434, 93, 10.1016/j.neulet.2008.01.034 · DOI
  78. Gómez-Ramos, 2006, Inhibition of GSK3 dependent tau phosphorylation by metals, Curr Alzheimer Res, 3, 123, 10.2174/156720506776383059 · DOI
  79. Rockenstein, 2007, Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation, J Neurosci, 27, 1981, 10.1523/JNEUROSCI.4321-06.2007 · DOI
  80. Caccamo, 2007, Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles, Am J Pathol, 170, 1669, 10.2353/ajpath.2007.061178 · DOI
  81. Hampel, 2008, Lithium trial in Alzheimer's disease: A randomized, single-blinded, placebo-controlled, parallel group multicentre 10-week study, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 4, T782, 10.1016/j.jalz.2008.05.2440 · DOI
  82. Deiana S, Harrington CR, Wischik CM, et al. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 2008; epub ahead of print. · DOI
  83. Nunomura, 2006, Involvement of oxidative stress in Alzheimer disease, J Neuropathol Exp Neurol, 65, 631, 10.1097/01.jnen.0000228136.58062.bf · DOI · Paper page
  84. Markesbery, 1999, Oxidative alterations in Alzheimer's disease, Brain Pathol, 9, 133, 10.1111/j.1750-3639.1999.tb00215.x · DOI
  85. Keller, 2005, Evidence of increased oxidative damage in subjects with mild cognitive impairment, Neurology, 64, 1152, 10.1212/01.WNL.0000156156.13641.BA · DOI · Paper page
  86. Engelhart, 2002, Dietary intake of antioxidants and risk of Alzheimer disease, JAMA, 287, 3223, 10.1001/jama.287.24.3223 · DOI · Paper page
  87. Lewis, 1992, Vitamin A and Alzheimer's disease, Neuroepidemiology, 11, 163, 10.1159/000110927 · DOI
  88. Zandi, 2004, Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study, Arch Neurol, 61, 82, 10.1001/archneur.61.1.82 · DOI · Paper page
  89. Masaki, 2000, Association of vitamin E and C supplement use with cognitive function and dementia in elderly men, Neurology, 54, 1265, 10.1212/WNL.54.6.1265 · DOI · Paper page
  90. Wadsworth, 2008, Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease, J Alzheimers Dis, 14, 225, 10.3233/JAD-2008-14210 · DOI
  91. Young, 2007, Coenzyme Q10: a review of its promise as a neuroprotectant, CNS Spectr, 12, 62, 10.1017/S1092852900020538 · DOI
  92. Morris, 2003, Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease, Arch Neurol, 60, 940, 10.1001/archneur.60.7.940 · DOI · Paper page
  93. Miller, 2005, Meta analysis: High dosage vitamin E supplementation may increase all-cause mortality, Ann Intern Med, 142, 37, 10.7326/0003-4819-142-1-200501040-00110 · DOI · Paper page
  94. Isaac, 2000, Vitamin E for Alzheimer's disease and mild cognitive impairment, Cochrane Database of Systematic Reviews, 4, CD002854
  95. Lee, 2004, Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?, Am J Clin Nutr, 80, 1194, 10.1093/ajcn/80.5.1194 · DOI
  96. Boothby, 2005, Vitamin C and vitamin E for Alzheimer's disease, Ann Pharmacother, 39, 2073, 10.1345/aph.1E495 · DOI
  97. Barberger-Gateau, 2007, Dietary patterns and risk of dementia: the Three-City cohort study, Neurology, 69, 1921, 10.1212/01.wnl.0000278116.37320.52 · DOI · Paper page
  98. Orr, 2008, The emerging role of docosahexaenoic acid in neuroinflammation, Curr Opin Investig Drugs, 9, 735
  99. Holmquist, 2007, Lipoic acid as a novel treatment for Alzheimer's disease and related dementias, Pharmacol Ther, 113, 154, 10.1016/j.pharmthera.2006.07.001 · DOI
  100. Lovell, 2003, Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid, J Alzheimers Dis., 5, 229, 10.3233/JAD-2003-5306 · DOI
  101. Moreira, 2007, Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts, J Alzheimers Dis, 12, 195, 10.3233/JAD-2007-12210 · DOI
  102. Maczurek, 2008, Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease, Adv Drug Deliv Rev, 60, 1463, 10.1016/j.addr.2008.04.015 · DOI
  103. Hager, 2007, Alpha-lipoic acid as a new treatment option for Alzheimer's disease—a 48 months follow-up analysis, J Neural Transm Suppl, 72, 189
  104. Ramassamy, 2007, Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?, Curr Alzheimer Res, 4, 253, 10.2174/156720507781077304 · DOI
  105. Luo, 2002, Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761, Proc Natl Acad Sci U S A, 99, 12197, 10.1073/pnas.182425199 · DOI
  106. Andrieu, 2003, Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study, J Gerontol A Biol Sci Med Sci, 58, 372, 10.1093/gerona/58.4.M372 · DOI
  107. Schneider, 2005, A randomized, double-blind, placebocontrolled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type, Curr Alzheimer Res, 2, 541, 10.2174/156720505774932287 · DOI
  108. Van Dongen, 2003, Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial, J Clin Epidemiol, 56, 367, 10.1016/S0895-4356(03)00003-9 · DOI
  109. Van Dongen, 2000, The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial, J Am Geriatr Soc, 48, 1183, 10.1111/j.1532-5415.2000.tb02589.x · DOI
  110. Kanowski, 2003, Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial, Pharmacopsychiatry, 36, 297, 10.1055/s-2003-45117 · DOI
  111. Le Bars, 2000, A 26-week analysis of a double-blind, placebocontrolled trial of the ginkgo biloba extract EGb 761 in dementia, Dement Geriatr Cogn Disord, 11, 230, 10.1159/000017242 · DOI
  112. Kurz, 2004, Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration, Dement Geriatr Cogn Disord, 18, 217, 10.1159/000079388 · DOI
  113. Mazza, 2006, Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled doubleblind study, Eur J Neurol, 13, 981, 10.1111/j.1468-1331.2006.01409.x · DOI
  114. Tauskela, 2007, MitoQ—a mitochondria-targeted antioxidant, IDrugs, 10, 399
  115. Wang, 2007, Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5, Neurochem Res, 32, 1329, 10.1007/s11064-007-9308-y · DOI
  116. Srinivasan, 2005, Role of melatonin in neurodegenerative diseases, Neurotox Res, 7, 293, 10.1007/BF03033887 · DOI
  117. Wang, 2006, Role of melatonin in Alzheimer-like neurodegeneration, Acta Pharmacol Sin, 27, 41, 10.1111/j.1745-7254.2006.00260.x · DOI
  118. Gupta, 2003, Inflammation and Alzheimer's disease, Int J Clin Pract, 57, 36, 10.1111/j.1742-1241.2003.tb11394.x · DOI
  119. Zandi, 2002, Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study, Neurology, 59, 880, 10.1212/WNL.59.6.880 · DOI
  120. Szekely, 2008, NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type, Neurology, 70, 17, 10.1212/01.wnl.0000284596.95156.48 · DOI · Paper page
  121. Rogers, 1993, Clinical trial of indomethacin in Alzheimer's disease, Neurology, 43, 1609, 10.1212/WNL.43.8.1609 · DOI
  122. Tabet N, Feldman H. Indomethacin for Alzheimer's disease. Cochrane Database of Systematic Reviews 2002;2:CD003673. · DOI
  123. de Jong, 2008, No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial, PLoS ONE., 3, e1475, 10.1371/journal.pone.0001475 · DOI
  124. Tabet, 2003, Ibuprofen for Alzheimer's disease, Cochrane Database Syst Rev, 2, CD004031
  125. Reines, 2004, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology, 62, 66, 10.1212/WNL.62.1.66 · DOI
  126. Soininen, 2007, Long-term efficacy and safety of celecoxib in Alzheimer's disease, Dement Geriatr Cogn Disord, 23, 8, 10.1159/000096588 · DOI
  127. Aisen, 2003, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA, 289, 2819, 10.1001/jama.289.21.2819 · DOI · Paper page
  128. Geerts, 2007, Drug evaluation: (R)-flurbiprofen—an enantiomer of flurbiprofen for the treatment of Alzheimer's disease, IDrugs, 10, 121
  129. Brode, 2008, Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide, Crit Rev Immunol, 28, 109, 10.1615/CritRevImmunol.v28.i2.20 · DOI
  130. Tobinick, 2008, Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration, J Neuroinflammation, 5, 2, 10.1186/1742-2094-5-2 · DOI
  131. Harikumar, 2008, Resveratrol: a multitargeted agent for age-associated chronic diseases, Cell Cycle, 7, 1020, 10.4161/cc.7.8.5740 · DOI
  132. Yang, 2005, Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo, J Biol Chem, 280, 5892, 10.1074/jbc.M404751200 · DOI · Paper page
  133. Greenamyre, 1989, Excitatory amino acids and Alzheimer's disease, Neurobiol Aging, 10, 593, 10.1016/0197-4580(89)90143-7 · DOI
  134. Chohan, 2006, From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease, J Alzheimers Dis, 10, 81, 10.3233/JAD-2006-10112 · DOI
  135. Parsons, 2007, Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse, Neuropharmacology, 53, 699, 10.1016/j.neuropharm.2007.07.013 · DOI
  136. Farlow, 2004, NMDA receptor antagonists, A new therapeutic approach for Alzheimer's disease. Geriatrics, 59, 22
  137. Lipton, 2007, Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation, Curr Drug Targets, 8, 621, 10.2174/138945007780618472 · DOI
  138. Zoladz, 2006, Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane, Pharmacol Biochem Behav, 85, 298, 10.1016/j.pbb.2006.08.011 · DOI
  139. Dicou, 2003, Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain, Brain Res, 970, 221, 10.1016/S0006-8993(03)02357-6 · DOI
  140. Quirk, 2002, LY404187: a novel positive allosteric modulator of AMPA receptors, CNS Drug Rev, 8, 255, 10.1111/j.1527-3458.2002.tb00228.x · DOI
  141. Fumagalli, 2006, The expanding role of BDNF: a therapeutic target for Alzheimer's disease?, Pharmacogenomics J, 6, 8, 10.1038/sj.tpj.6500337 · DOI
  142. Conner, 2001, Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation, Proc Natl Acad Sci U S A, 98, 1941, 10.1073/pnas.98.4.1941 · DOI
  143. Capsoni, 2002, Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice, Proc Natl Acad Sci U S A, 99, 12432, 10.1073/pnas.192442999 · DOI
  144. Grundman, 2003, A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients, Life Sci, 73, 539, 10.1016/S0024-3205(03)00320-5 · DOI
  145. Sugaya, 2006, Stem cell strategies for Alzheimer's disease therapy, Panminerva Med, 48, 87
  146. Oliveira, 2005, Alzheimer's disease and neural transplantation as prospective cell therapy, Curr Alzheimer Res, 2, 79, 10.2174/1567205052772759 · DOI
  147. Elder, 2006, Research update: neurogenesis in adult brain and neuropsychiatric disorders, Mt Sinai J Med, 73, 931
  148. Lovell, 2006, Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain, Neurobiol Aging, 27, 909, 10.1016/j.neurobiolaging.2005.05.004 · DOI
  149. Pagocic, 2007, List of drugs in development for neurodegenerative diseases, Neurodegenerative Dis, 4, 443, 10.1159/000107705 · DOI
  150. Ballard, 2005, Cholinesterases: roles in the brain during health and disease, Curr Alzheimer Res, 2, 307, 10.2174/1567205054367838 · DOI
  151. Mori, 2006, What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?, Alzheimer Dis Assoc Disord, 20, S19, 10.1097/01.wad.0000213805.66811.31 · DOI
  152. Li, 2008, Huperzine A for Alzheimer's disease, Cochrane Database Syst Rev, 2, CD005592
  153. Wang, 2005, Neuroprotective effects of huperzine A, A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals, 14, 71
  154. Greig, 2005, An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, Curr Alzheimer Res, 2, 281, 10.2174/1567205054367829 · DOI
  155. Kadir, 2008, Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease, Ann Neurol, 63, 621, 10.1002/ana.21345 · DOI
  156. Lahiri, 2007, The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice, J Pharmacol Exp Ther, 320, 386, 10.1124/jpet.106.112102 · DOI
  157. Klein, 2007, Phenserine, Expert Opin Investig Drugs, 16, 1087, 10.1517/13543784.16.7.1087 · DOI
  158. Lane, 2006, Targeting acetylcholinesterase and butyrylcholinesterase in dementia, Int J Neuropsychopharmacol, 9, 101, 10.1017/S1461145705005833 · DOI · Paper page
  159. Kamal, 2006, Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine, Biochim Biophys Acta, 1760, 200, 10.1016/j.bbagen.2005.10.003 · DOI
  160. Kamal, 2006, Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine, J Alzheimers Dis, 10, 43, 10.3233/JAD-2006-10108 · DOI
  161. Thal, 2000, Lu 25–109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease, Neurology, 54, 421, 10.1212/WNL.54.2.421 · DOI
  162. Messer, 2002, The utility of muscarinic agonists in the treatment of Alzheimer's disease, J Mol Neurosci, 19, 187, 10.1007/s12031-002-0031-5 · DOI
  163. isher, 2003, M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy, J Mol Neurosci, 20, 349, 10.1385/JMN:20:3:349 · DOI
  164. Caccamo, 2006, M1 receptors play a central role in modulating AD-like pathology in transgenic mice, Neuron, 49, 671, 10.1016/j.neuron.2006.01.020 · DOI · Paper page
  165. Wienrich, 2001, Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man, Life Sci, 68, 2593, 10.1016/S0024-3205(01)01057-8 · DOI
  166. Hock, 2003, Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease, Amyloid, 10, 1, 10.3109/13506120308995249 · DOI
  167. Arneric, 1995, Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties, Alzheimer Dis Assoc Disord, 9, 50, 10.1097/00002093-199501002-00009 · DOI
  168. Lippiello, 1996, RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization, J Pharmacol Exp Ther, 279, 1422, 10.1016/S0022-3565(25)21303-9 · DOI
  169. Bencherif, 2000, TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors, Eur J Pharmacol, 409, 45, 10.1016/S0014-2999(00)00807-4 · DOI
  170. Lippiello, 2006, Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties, J Mol Neurosci, 30, 19, 10.1385/JMN:30:1:19 · DOI
  171. Lin, 1997, Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties, J Med Chem, 40, 385, 10.1021/jm960233u · DOI · Paper page
  172. Kem, 2000, The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21), Behav Brain Res, 113, 169, 10.1016/S0166-4328(00)00211-4 · DOI
  173. Williamson, 2007, The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods, Am J Cardiol, 99, 112, 10.1016/j.amjcard.2007.03.029 · DOI
  174. Rönnemaa, 2008, Impaired insulin secretion increases the risk of Alzheimer disease, Neurology, 71, 1065, 10.1212/01.wnl.0000310646.32212.3a · DOI
  175. Sabayan, 2008, Role of Insulin Metabolism Disturbances in the Development of Alzheimer Disease: Mini Review, Am J Alzheimers Dis Other Demen, 23, 192, 10.1177/1533317507312623 · DOI
  176. Craft, 2007, Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment, Curr Alzheimer Res, 4, 147, 10.2174/156720507780362137 · DOI · Paper page
  177. Gasparini, 2001, Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling, J Neurosci, 21, 2561, 10.1523/JNEUROSCI.21-08-02561.2001 · DOI
  178. Reger, 2008, Intranasal insulin improves cognition and modulates beta-amyloid in early AD, Neurology, 70, 440, 10.1212/01.WNL.0000265401.62434.36 · DOI · Paper page
  179. Watson, 2003, The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment, CNS Drugs, 17, 27, 10.2165/00023210-200317010-00003 · DOI
  180. Watson, 2005, Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study, Am J Geriatr Psychiatry, 13, 950
  181. Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 · DOI · Paper page
  182. Reger, 2004, Effects of beta-hydroxybutyrate on cognition in memory-impaired adults, Neurobiol Aging, 25, 311, 10.1016/S0197-4580(03)00087-3 · DOI
  183. Yaffe, 1998, Estrogen therapy in postmenopausal women: effects on cognitive function and dementia, JAMA, 279, 688, 10.1001/jama.279.9.688 · DOI
  184. Hogervorst, 2000, The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis, Neuroscience, 101, 485, 10.1016/S0306-4522(00)00410-3 · DOI
  185. LeBlanc, 2002, Estrogen and Alzheimer's disease, Curr Opin Investig Drugs, 3, 768
  186. Maki, 2003, The menopause and HRT. HRT and cognitive decline, Best Pract Res Clin Endocrinol Metab, 17, 105, 10.1016/S1521-690X(02)00082-9 · DOI
  187. Webber, 2007, The contribution of luteinizing hormone to Alzheimer disease pathogenesis, Clin Med Res, 5, 177, 10.3121/cmr.2007.741 · DOI
  188. Webber, 2007, Gonadotropins: a cohesive gender-based etiology of Alzheimer disease, Mol Cell Endocrinol, 260–262, 271, 10.1016/j.mce.2006.01.018 · DOI
  189. Short, 2001, Elevated gonadotropin levels in patients with Alzheimer disease, Mayo Clin Proc, 76, 906, 10.1016/S0025-6196(11)62109-5 · DOI
  190. Bowen, 2002, Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology, J Neurosci Res, 70, 514, 10.1002/jnr.10452 · DOI
  191. Casadesus, 2006, The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease, Drugs R D, 7, 187, 10.2165/00126839-200607030-00004 · DOI
  192. Meethal, 2005, The gonadotropin connection in Alzheimer's disease, Endocrine, 26, 317, 10.1385/ENDO:26:3:317 · DOI
  193. Cherrier, 2005, Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment, Neurology, 64, 2063, 10.1212/01.WNL.0000165995.98986.F1 · DOI
  194. Lu, 2006, Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men, Arch Neurol, 63, 177, 10.1001/archneur.63.2.nct50002 · DOI
  195. Cherrier, 2001, Testosterone supplementation improves spatial and verbal memory in healthy older men, Neurology, 57, 80, 10.1212/WNL.57.1.80 · DOI
  196. Merriam, 2003, Growth hormone-releasing hormone and growth hormone secretagogues in normal aging, Endocrine, 22, 41, 10.1385/ENDO:22:1:41 · DOI
  197. Vitiello, 2006, Growth hormone releasing hormone improves the cognition of healthy older adults, Neurobiol Aging, 27, 318, 10.1016/j.neurobiolaging.2005.01.010 · DOI
  198. Sevigny, 2008, Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial, Neurology., 18;71, 1702, 10.1212/01.wnl.0000335163.88054.e7 · DOI
  199. Hibberd, 2000, Glucocorticoids and the ageing hippocampus, J Anat, 197, 553, 10.1046/j.1469-7580.2000.19740553.x · DOI
  200. Green, 2006, Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease, J Neurosci, 26, 9047, 10.1523/JNEUROSCI.2797-06.2006 · DOI · Paper page

200 of 222 shown

Cited by

Sorted by citations

See all 32

Metadata

Authors
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B.
Venue
The Journal of nutrition, health and aging
Publisher
Elsevier BV
Published
2011-01
Volume
15
Issue
1
Pages
45-57
ISSN
1279-7707
DOI
10.1007/s12603-011-0012-x
PMC
PMC12879621
Cited by
32
References
28
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review